6 completed, 4 not yet recruiting, 3 recruiting. 7 Phase 2, 6 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Not yet recruiting 3, Completed 2, Recruiting 2 |
| Not applicable | 6 | Completed 4, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow 2-(aminomethyl)phenol: new trials by email Literature Review of 2-(aminomethyl)phenol trials Research Report on 2-(aminomethyl)phenol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension 2-HOBA - Pulmonary Arterial Hypertension | Phase 2 | Not yet recruiting | Vanderbilt University Medical Center | 12 | 2026-09-01 | 2026-06-17 |
| Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans 2-hydroxybenzylamine, Placebo - Salt Sensitivity of Blood Pressure, High Blood Pressure | Phase 2 | Not yet recruiting | Vanderbilt University Medical Center | 20 | 2026-09-01 | 2026-07-28 |
| 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients 2-hydroxybenzylamine acetate, Placebo - Alzheimer Disease, Mild Cognitive Impairment | Phase 1 / Phase 2 | Not yet recruiting | MTI Biotech Inc | 48 | 2026-09-01 | 2026-09-24 |
| 2-HOBA in Systemic Lupus Erythematosus 2-HOBA acetate (2-Hydroxybenzlamine acetate), Placebo - Systemic Lupus Erthematosus (SLE) | Phase 2 | Recruiting | Vanderbilt University Medical Center | 42 | 2026-05-15 | 2026-05-22 |
| This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65. β-Hydroxy-β-methylbutyrate, 2-hydroxybenzylamine, β-Hydroxy-β-methylbutyrate and 2-hydroxybenzylamine - Muscle, Cognitive Functioning | Not applicable | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 120 | 2026-03-06 | 2026-05-14 |
| 2-HOBA Supplementation in People With Elevated Lipoprotein(a) 2-HOBA (Hobamine) - Hyperlipidemia, Elevated Lp(a) | Not applicable | Not yet recruiting | The Miriam Hospital | 10 | 2025-11-01 | 2025-09-30 |
| 2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH) 2-Hydroxybenzylamine, Placebo - Familial Hypercholesterolemia | Phase 2 | Recruiting | Vanderbilt University Medical Center | 72 | 2024-02-14 | 2026-08-07 |
| 2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis 2-HOBA, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Vanderbilt University Medical Center | 32 | 2022-08-09 | 2026-04-08 |
| 2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation 2-Hydroxybenzylamine, Placebo - Atrial Fibrillation | Phase 2 | Completed | Vanderbilt University Medical Center | 95 | 2020-05-15 | 2024-11-21 |
| 2-HOBA: Multiple Dosing Study in Older Adults 2-HOBA, Placebo - Older Adults | Not applicable | Completed | Metabolic Technologies Inc. | 18 | 2018-05-23 | 2021-12-14 |
| 2-HOBA: Multiple Dosing Study in Healthy Humans 2-HOBA, Placebo - Healthy Volunteers | Not applicable | Completed | Metabolic Technologies Inc. | 18 | 2018-05-23 | 2019-08-13 |
| Brain Penetrance of 2-HOBA in Humans 2-HOBA - Healthy Adults | Not applicable | Completed | Metabolic Technologies Inc. | 3 | 2018-05-23 | 2019-02-20 |
| 2-HOBA: Initial Evaluation in Humans 2-HOBA - Healthy Volunteers | Not applicable | Completed | Metabolic Technologies Inc. | 18 | 2017-08-02 | 2018-06-04 |
Hypertension (2) · Alzheimer Disease (1) · Arthritis, Rheumatoid (1) · Atrial Fibrillation (1) · Cognitive Dysfunction (1) · Hyperlipidemias (1) · Hyperlipoproteinemia Type II (1) · Hypertension, Pulmonary (1) · Inflammation (1) · Lupus Erythematosus, Systemic (1) · Pulmonary Arterial Hypertension (1)
Vanderbilt University Medical Center (6) · Metabolic Technologies Inc. (4) · MTI Biotech Inc (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · The Miriam Hospital (1)
United States (11) · Canada (1)
John A Rathmacher, PhD (4) · Ben Shoemaker, MD (1) · Gustavo Duque, Medical Doctor (1) · John A. Rathmacher, Ph.D. (1) · MacRae F. Linton, MD (1) · Michelle J Ormseth, MD, MSCI (1) · Michelle Ormseth, MD, MSCI (1) · Patricia Andrews, M.D. (1) · Paul A. Newhouse, M.D. (1) · Wenliang Song, MD (1)
PMID 31907026, PMID 11230313, PMID 12147930, PMID 1846122, PMID 1860713, PMID 1879381, PMID 30611293, PMID 34454591, PMID 3522418, PMID 37534363, PMID 37675576, PMID 41052782
R44AG055184 (4), P01HL116263 (1), P01HL174442 (1)